Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have revolutionized cancer treatment. However, fewer than 20% of patients respond to these treatments, highlighting the urgent need for new strategies tailored to both responders and non-responders.
KAIST researchers have discovered that ‘DEAD-box helicases 54 (DDX54)’, a type ofRNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy — opening…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply